Antinociceptive Interactions between Intrathecal Gabapentin and MK801 or NBQX in Rat Formalin Test by Yoon, Myung Ha et al.
INTRODUCTION
Gabapentin is a novel antiepileptic agent and a structural
analog to  -aminobutyric acid (GABA) (1). Studies of the
activity profile of gabapentin have shown that intrathecal
gabapentin counteracts injury-induced hyperalgesia, but it
does not reduce acute nociception (2-4). Although the specif-
ic mechanism of gabapentin’s antinociception is not certain,
N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-
5-methtyl-4-isoxazolepropionate (AMPA) receptors have been
suggested as sites of action in the spinal cord (5). 
Glutamate, the excitatory amino acid (EAA), is involved
in the transmission of nociceptive information in the spinal
cord (6). The excitatory effect of glutamate is considered to
be mediated through at least two distinct classes of receptors,
NMDA and AMPA receptors (7-9). Intrathecal NMDA anta-
gonists have various effects on acute nociception, but they
inhibit injury-induced hyperalgesia (10-15). On the other
hand, intrathecal AMPA antagonists alleviate acute nocicep-
tion with different effects on injury-induced hyperalgesia
(2, 7, 16).
These observations suggest that spinal gabapentin, NMDA
antagonists and AMPA antagonists may or may not be against
nociception according to the nociceptive conditions. However,
there has been little data regarding the interaction between
gabapentin and antagonists for NMDA or AMPA receptors
at the spinal level in the formalin test, which is a preclinical
pain model showing acute nociception followed by injury-
induced hyperalgesia. 
The aim of this study was threefold: 1) to examine the effect
of intrathecal gabapentin, NMDA antagonist (MK801) and
AMPA antagonist (NBQX) in the rat formalin test, 2) to eval-
uate the consequence of gabapentin on the effect of MK801
or NBQX in acute nociception, and 3) to determine the spinal-
ly mediated antinociceptive interactions between gabapentin
and MK801 or NBQX in the injury-induced hyperalgesia. 
MATERIALS AND METHODS
This work was carried out with permission from the Ani-
mal Care Committee of our Research Institute of Medical
Science. 
Male Sprague-Dawley rats (250-300 g) were used. Rats
were housed in group cages and kept in a vivarium, main-
tained at 22℃ with a 12 hr alternating night/day cycle, and
were given water and food ad libitum. For drug administra-
tion, intrathecal catheters were advanced caudally 8.5 cm into
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Antinociceptive Interactions between Intrathecal Gabapentin and
MK801 or NBQX in Rat Formalin Test
Antagonists for spinal N-methyl-D-aspartate (NMDA) and amino-hydroxy-methtyl-
isoxazolepropionate (AMPA) receptors are effective in attenuating acute nocicep-
tion or injury-induced hyperalgesia. The antinociception of spinal gabapentin is
developed in injury-induced hyperalgesia without affecting acute nociception. The
authors evaluated the effects of intrathecal gabapentin, NMDA antagonist (MK801)
and AMPA antagonist (NBQX) in the formalin test which shows injury-induced
hyperalgesia as well as acute pain. We further assessed the interactions between
gabapentin and either MK801 or NBQX. Male Sprague-Dawley rats were implant-
ed with intrathecal catheters. To evoke pain, 50  L of 5% formalin solution was
injected into the hindpaw. The interaction was investigated by a fixed dose analy-
sis or an isobolographic analysis. MK801 and NBQX suppressed flinching respons-
es during phase 1 of the formalin test, while gabapentin had little effect on phase
1. All three agents decreased the phase 2 flinching response. A fixed dose analy-
sis in phase 1 showed that gabapentin potentiated the antinociceptive effect of
MK801 and NBQX. Isobolographic analysis in phase 2 revealed a synergistic
interaction after coadministration of gabapentin-MK801 or gabapentin-NBQX. Cor-
respondingly, spinal gabapentin with NMDA or AMPA antagonist may be useful in
managing acute pain and injury-induced hyperalgesia.
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the subarachnoid space through an incision in the atlantooc-
cipital membrane during enflurane anesthesia (17).
Rats showing postoperative neurologic sequelae were im-
mediately killed with an overdose of volatile anesthetics. After
surgery, the rats were kept in individual cages and allowed
to recover for 4-5 days.
The following drugs were used in this study: gabapentin
(1-[aminomethyl] cyclohexanacetic acid; Sigma Chemical
Co., St. Louis, MO, U.S.A.), MK801 (NMDA receptor anta-
gonist; Research Biochemical Internationals [RBI], Natick,
U.S.A.) and NBQX (AMPA receptor antagonist; Tocris Cook-
son Ltd., Bristol, U.K.). Gabapentin and MK801 were dis-
solved in normal saline. NBQX was dissolved in dimethyl-
sulfoxide (DMSO). Intrathecal administration of these agents
was performed using a hand-driven, gear-operated syringe
pump. All drugs were given in a volume of 10  L solution,
followed by an additional 10  L of normal saline to flush the
catheter. 
The formalin test was used as a nociceptive test (4). 50  L
of 5% formalin solution was injected subcutaneously into the
plantar surface of the hindpaw. After formalin injection, rats
show a characteristic pain behavior, biphasic flinching/shaking
of the injected paw. Such pain behavior was therefore quan-
tified. The interval from 0-9 and 10-60 min after the forma-
lin injection was defined as phase 1 and phase 2 of the forma-
lin test, respectively. Upon completion of the 60 min obser-
vation, the rats were immediately killed with an overdose of
volatile anesthetics.
Animals were behaviorally tested four to five days after
intrathecal catheterization. After acclimation for 15-20 min
in a restraint cylinder, rats were then placed into one of the
experimental groups. The drug vehicles (saline or DMSO)
were used as a control for intrathecal drugs. The rats were
only used once. 
The first series of experiments were performed to examine
the time course and dose-dependency of intrathecal gabapen-
tin (10, 30, 100 and 300  g), MK801 (3, 10 and 30  g) and
NBQX (0.3, 1 and 3 g) in the formalin test. Intrathecal drugs
were given 10 min before the formalin injection. Each ED50
value (effective dose producing a 50% reduction of control
formalin response) of three agents was separately determined
in two phases.
To determine the characteristics of interaction between gaba-
pentin and the NMDA antagonist, or between gabapentin and
the AMPA antagonist, a fixed dose analysis and an isobolo-
graphic analysis were used (18). 
A fixed dose analysis was used in phase 1 because intrathe-
cal gabapentin did not produce an antinociceptive effect dur-
ing phase 1. A fixed dose of gabapentin (300  g) was intrathe-
cally coadministered with various doses of MK801 or NBQX.
An isobolographic analysis was used to define the property
of interaction during phase 2. This method is based on com-
parisons of doses that are determined to be equally effective.
First, each ED50 value was determined from the dose-response.
Then, the ED50 values of the mixture were calculated from
the dose-response curves of the combined drugs and used for
plotting the isobologram. In order to understand the mag-
nitude of the interaction, a total fraction value was also cal-
culated. 
Total fraction value 
=ED50 [(drug 1+drug 2)/drug 1+(drug 2+drug 1)/drug 2]
The fraction values indicate what portion of the single ED50
value was accounted for by the corresponding ED50 value for
the combination. Values near 1 indicate an additive interac-
tion, values greater than 1 imply an antagonistic interaction
and values less than 1 indicate a synergistic interaction. The
mixtures were delivered intrathecally 10 min before the for-
malin test. 
To examine the behavioral changes by gabapentin, MK801
and NBQX, the highest dose of each drug was given intrathe-
cally to the additional rats. Motor function was assessed by
the placing-stepping reflex and the righting reflex (14). The
first was evoked by drawing the dorsum of either hind paw
across the edge of the table. Healthy rats generally try to put
the paw ahead into a position for walking. The other was eval-
uated by placing the rat horizontally with its back on the table.
Healthy rats give rise to an immediate and coordinated twist-
ing of the body into an upright position. 
Data are expressed with a mean±SEM. The time-response
data are presented as the number of flinches. The dose-res-
ponse data are presented as the total sum of flinches in each
phase. To calculate the ED50 values of each drug, the number
of flinches was converted into percentage of control accord-
ing to the following formula:
Sum of phase 1 (or 2) count with drug  % of control=--------------------------------------------------------------------------×100 Sum of control phase 1 (or 2) count
Dose-response data were analyzed by one-way analysis of
variance (ANOVA) with Scheffe for post hoc. The dose-res-
ponse lines were fitted using least-squares linear regression and
ED50 and its 95% confidence intervals were calculated accord-
ing to the method described by Tallarida and Murray (19).
The difference between theoretical ED50 and experimental
ED50 was examined by t-test. A p value less than 0.05 was
considered significant.
RESULTS
A biphasic flinching response of the injected paw was ob-
served in all rats after subcutaneous injection of formalin into
the hindpaw. 
Fig. 1 displays the time course of intrathecal gabapentin,
MK801 and NBQX in the formalin test. The sum of the
number of flinches in the control group did not differ statis-
tically in either phase (saline vs. DMSO: 20±2 vs. 20±1 in
phase 1, 160±8 vs. 158±13 in phase 2). Intrathecal MK801Interaction between Gabapentin and MK801 or NBQX 309
and NBQX, but not gabapentin, produced a dose-dependent
reduction of flinching response during phase 1 (Fig. 2A). Dur-
ing phase 2, all three drugs produced a dose-dependent sup-
pression of flinching response (Fig. 2B). 
Intrathecal coadministration of MK801 and NBQX with
a fixed dose of gabapentin in phase 1 increased the antinoci-
ceptive effect of MK801 and NBQX (Fig. 3A, 4A). Isobolo-
graphic analysis revealed a synergistic interaction after the
concurrent delivery of mixtures of gabapentin-MK801 and
gabapentin-NBQX during phase 2 in the formalin test. These
experimental ED50 values were significantly lower than those
of the theoretical ED50 values (Fig. 3B, 4B) with a total frac-
tion value of less than 1, indicating a synergistic interaction
(Table 1). 
Intrathecal gabapentin, MK801 and NBQX did not cause
any change of motor tone.
DISCUSSION
In the current work, intrathecal gabapentin was active only
against the phase 2 flinching response, which implicates that
gabapentin may be effective in attenuating the injury-induced
hyperalgesia without affecting acute nociception at the spinal
level. These results were consistent with those of previous
experiments (2-4). Although the antinociceptive mechanisms
of gabapentin remains unclear, several targets have been pro-
posed. It has been reported that gabapentin increases the con-
centration, the rate of synthesis and the release of GABA (1).
But intrathecal GABAA or GABAB receptor antagonists failed
to reverse the antinociception of gabapentin (5). On the other
F
l
i
n
c
h
e
s
/
m
i
n
30
25
20
15
10
5
0
01 0 2 0 3 0 4 0 5 0 6 0
Time (min)
Gabapentin
MK 801
saline
10 g
30 g
100 g
300 g
saline
3 g
10 g
30 g
F
l
i
n
c
h
e
s
/
m
i
n
30
25
20
15
10
5
0
01 0 2 0 3 0 4 0 5 0 6 0
Time (min)
Fig. 1. Time effect curve of intrathecal gabapentin (A), MK801 (B)
and NBQX (C) for flinching response in the formalin test. Each
drug was administered 10 min before formalin injection (F). Data
are presented as the number of flinches. Each line represents
the mean±SEM of 6-8 rats.
NBQX DMSO
0.3 g
1 g
3 g
F
l
i
n
c
h
e
s
/
m
i
n
25
20
15
10
5
0
01 0 2 0 3 0 4 0 5 0 6 0
F
Time (min)
S
u
m
 
o
f
 
F
l
i
n
c
h
e
s
30
25
20
15
10
5
0
0.1 1 10 100
Dose ( g)
Phase 1
Fig. 2. Dose response curve of intrathecal gabapentin, MK801
and NBQX for flinching response during phase 1 (A) and phase
2 (B) in the formalin test. Data are presented as the total sum of
flinches in each phase. Gabapentin reduces flinches in phase 2
but not in phase 1. MK801 and NBQX produce a dose-depen-
dent inhibition of flinches in both phases. Each line represents the
mean±SEM of 6-8 rats. Compared with saline or DMSO, *p<0.01,
� p<0.001.
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hand, NMDA and AMPA receptors were reported to be in-
volved in gabapentin-induced antinociception (5). Addition-
ally, gabapentin has been shown to bind specifically to the
2 subunit of voltage-sensitive calcium channels (20).
In this study, intrathecal MK801 and NBQX resulted in
a dose-dependent inhibition of flinching response in both
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Fig. 3. A fixed dose analysis (A) for the interaction between intrathecal gabapentin (300  g) and MK 801 during phase 1 and isobolo-
gram (B) for the interaction between gabapentin and MK 801 during phase 2 in the formalin test. Data for a fixed dose analysis are pre-
sented as the sum of flinches. At a fixed dose analysis, addition of gabapentin to MK 801 was significantly different from that of MK 801
alone, which means that gabapentin increased the antinociception of MK 801. At an isobologram, the ED50 values for each agent are
plotted on the x- and y-axes, respectively, and the thick lines represent the S.E.M. of the ED50. The straight line connecting each ED50
value is the theoretical additive line and the point on this line is the theoretical additive ED50. The experimental ED50 point was significantly
different from the theoretical ED50 point, indicating a synergistic interaction. Each line represents the mean±SEM of 5-8 rats. Compared
with MK 801, *p<0.01, 
� p<0.001.
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Fig. 4. A fixed dose analysis (A) for the interaction between intrathecal gabapentin (300  g) and NBQX during phase 1 and isobologram
(B) for the interaction between gabapentin and NBQX during phase 2 in the formalin test. Data for a fixed dose analysis are presented as
the sum of flinches. At a fixed dose analysis, addition of gabapentin to NBQX was significantly different from that of NBQX alone, which
means that gabapentin increased the antinociception of NBQX. At an isobologram, the ED50 values for each agent are plotted on the x-
and y-axes, respectively, and the thick lines represent the S.E.M. of the ED50. The straight line connecting each ED50 value is the theoreti-
cal additive line and the point on this line is the theoretical additive ED50. The experimental ED50 point was significantly different from the
theoretical ED50 point, indicating a synergistic interaction. Each line represents the mean±SEM of 5-7 rats. Compared with NBQX, *p<0.05. 
N
B
Q
X
 
(
g
)
1.8
1.5
1.2
0.9
0.6
0.3
0.0
0 20 40 60 80 100
Gabapentin ( g)
*
* Theoretical ED50
Experimental ED50
NBQX
NBQX+Gabapentin
A B
NBQX
NBQX+Gabapentin
ED50, effective dose producing a 50% reduction of control formalin response; CI, confidence intervals.
*These values imply the ED50 values of gabapentin in the mixtures of gabapentin-MK801 and gabapentin-NBQX.
Gabapentin MK801 NBQX Gabapentin*+MK801 Gabapentin*+NBQX
No. of rats 29 21 22 29 27
ED50 (95% CI) phase 1 (     - 18.7 (11.1 to 31.4) 1.6 (1.2 to 2) (     - (    -
phase 2 76.4 (47.8 to 122.1) 11.4 (8.9 to 14.6) 1.6 (1 to 2.6) 25.4 (18 to 36) 20.6 (10.7 to 39.5)
Slope (95% CI) phase 1 (     - -55.1 (-79.6 to -30.6) -74.6 (-92.3 to -56.8) (     - (    -
phase 2 -40.5 (-55 to -26) -56.6 (-72.1 to -41.1) -50.8 (-73.2 to -28.3) -60.3 (-87.9 to -32.8) -32.6 (-55 to -10.3)
TFV - - - 0.58 0.54 
Table 1. ED50 ( g), slope and total fraction value (TFV) of intrathecal agents in the formalin testphases. These observations suggest that NMDA receptors
and AMPA receptors may be active in the modulation of the
injury-induced hyperalgesia as well as acute nociception at
the spinal level. 
EAAs, such as glutamate and aspartate, may play an impor-
tant role in nociceptive transmission in the dorsal horn of the
spinal cord (6). These EAAs have been considered to facili-
tate spinal sensory transmission and contribute to the enhanced
excitability of dorsal horn neurons through NMDA recep-
tors and non-NMDA receptors (8, 9). The NMDA receptors
exist in the substantia gelatinosa of the dorsal horn and are
postsynaptic to an interneuron mediating an excitation which
is responsible for the spinal nociceptive processing, including
injury-induced hyperalgesia (21-23). Thus, NMDA antago-
nists may attenuate the noxious inputs in a tonically active
state such as the phase 2 response of the formalin test. On
the other hand, AMPA receptors are present in the superfi-
cial lamina of the dorsal horn and mediate excitatory trans-
mission involving acute nociceptive inputs (24, 25). Hence,
AMPA antagonists may suppress acute excitation induced
by high intensity stimuli such as the phase 1 response of the
formalin test. Interestingly, in this study, spinal NMDA anta-
gonist and AMPA antagonist reduced not only the phase 1
response but also the phase 2 response. These findings sug-
gest that the NMDA receptor and the AMPA receptor may
be involved in the regulation of the injury-induced hyperal-
gesia as well as acute nociception in the spinal cord. The fact
that NMDA antagonist blocked the release of substance-P
(26) supports the phase 1 antinociception of MK801 observed
in this study. Additionally, the phase 2 response seems to
result from a continuous afferent input, which is produced
in phase 1. Thus, as the phase 1 component of the formalin
stimulus is gradually reduced by AMPA antagonist, the phase
2 response might also be decreased. This effect was observed
during phase 2 in this study with AMPA antagonist. 
Although NMDA antagonist and AMPA antagonist atte-
nuated both acute nociception and injury-induced hyperal-
gesia, the relative effectiveness of the drugs was noted. In
MK801-treated rats, ED50 in phase 2 was lower than that in
phase 1. Moreover, the ED50 value of NBQX in phase 1 was
similar to that in phase 2. These findings suggest that the
NMDA antagonist appears to be much more effective on
injury-induced hyperalgesia than on acute nociception. Addi-
tionally, AMPA antagonist shows similar effects for acute
nociception and injury-induced hyperalgesia. However, the
results observed in the present study are both consistent (11,
13, 15) and inconsistent with previous data (7, 10, 12, 14).
This discrepancy may be caused by the different types of test-
ed stimuli, kinds and doses of drugs administered and the
relative affinity or selectivity of the drugs. 
According to a fixed dose analysis performed in phase 1,
intrathecal gabapentin increased the antinociceptive effect
of MK801 and NBQX. Isobolographic analysis performed
in phase 2 indicated that intrathecal gabapentin showed a
synergistic effect with MK801 as well as with NBQX. These
results illustrate that spinal gabapentin can augment the anti-
nociceptive action of MK801 and NBQX for injury-induced
hyperalgesia as well as acute nociception. Previous studies
have shown that intrathecal gabapentin reinforced the effects
of clonidine or neostigmine for acute nociception (18). A syn-
ergistic interaction has been reported between gabapentin
and other analgesics, such as clonidine, naproxen and mor-
phine in numerous nociceptive conditions (16, 27, 28). Sev-
eral mechanisms would be possible for this synergistic inter-
action. First, drugs may interact by altering the kinetics of
each other. One agent may alter the actions of the other agent
at the receptor or channel, thereby leading to synergism. Sec-
ond, functional interaction may result from distinct drug
effects at separate anatomic sites that may act independently
and together to inhibit spinal nociceptive processing (29).
Thus, a decrease in excitatory neurotransmission with MK801
and NBQX accompanied by inhibiting calcium channels
with gabapentin in the spinal cord may lead to synergism.
This mechanism was observed in the synergistic interaction
of gabapentin and non-NMDA antagonist in a neuropathic
pain model of rats (30). Third, synergism may stem from the
characteristics of action of gabapentin. Gabapentin would
promote the activity of inhibitory neurons following inflam-
matory injuries (31) and thus the combination of gabapentin
with MK801 or NBQX may result in a greater reduction of
transmission of nociceptive signals, which may develop into
synergism. 
Altogether, intrathecal MK801 and NBQX, but not gaba-
pentin, reduced the phase 1 flinching response of the forma-
lin test, and all three drugs reduced the phase 2 flinching
response. Intrathecal gabapentin also increased the effects of
MK801 and NBQX during phase 1 of the formalin test and
interacted with MK801 and NBQX in a synergistic fashion
during phase 2. 
These results suggest that spinal NMDA and AMPA recep-
tors may be involved in the regulation of the injury-induced
hyperalgesia as well as acute nociception. Concurrent deliv-
ery of gabapentin with either NMDA antagonist or AMPA
antagonist may well have virtue in dealing with pain, as it
serves to reduce the required dose of each drug.
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